Skip to main content
RDY
NYSE Life Sciences

Dr. Reddy's Secures Brazil Approval for Generic Semaglutide Injection

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.75
Mkt Cap
$12.146B
52W Low
$11.36
52W High
$15.67
52W Position info
30% above low
Off High info
5.9% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

RDY sits 30% above its 52-week low of $11.36.

Summary

Brazil's ANVISA approved Dr. Reddy's generic semaglutide injection for type 2 diabetes, opening a market the company estimates at about USD 244.6 million. Dr. Reddy's plans to launch there with partner Aché; no launch date or financial terms were given.


Key Events · Product Development and Regulatory · RDY

  • ANVISA Approves Generic Semaglutide

    Brazil's regulator granted marketing authorization for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise.

  • Market Sized at ~$244.6M

    Dr. Reddy's cites IQVIA (MAT September 2026) putting the Brazilian semaglutide diabetes market at approximately USD 244.6 million, with 16.6 million adults aged 20-79 living with diabetes in Brazil.

  • Two Pen Presentations, Weekly Dosing

    The product will be sold as pre-filled multi-dose injectable pens in 2 mg/1.5 mL and 4 mg/3 mL strengths for once-weekly dosing.

  • Launch Planned With Aché

    CEO of Global Generics MV Ramana said Dr. Reddy's plans to launch semaglutide in Brazil with partner Aché; no launch date or pricing was disclosed.


Analysis · RDY · Life Sciences

ANVISA has cleared Dr. Reddy's generic semaglutide in Brazil, a diabetes market the company sizes at roughly USD 244.6 million — meaningful, though not transformative for a company of this scale. The approval extends the semaglutide franchise into a second major emerging market and comes with a named launch partner, Aché, sharing commercialization risk. Strategic weight lies in the GLP-1 build-out: Dr. Reddy's is positioning itself as a low-cost semaglutide supplier across markets, and each approval strengthens that case. Against a backdrop of USFDA observations at three Indian plants since August and a 36% year-over-year drop in Q2 FY2026 profit on weaker North America generics, emerging-market GLP-1 revenue offers a useful offset. No financial terms, launch date, or pricing were disclosed.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RDY was trading at $14.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDY - Latest Insights

RDY
Nov 03, 2026, 1:09 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $14.38
Real-time Price: $14.89 info
Change: +$0.514 (+4%) info
Market Cap: $12.445B info
RDY
Nov 02, 2026, 12:25 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $14.89 info
Change: +$0.795 (+6%) info
Market Cap: $12.445B info
RDY
Oct 23, 2026, 12:22 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.22
Real-time Price: $14.89 info
Change: +$1.68 (+13%) info
Market Cap: $12.445B info
RDY
Oct 14, 2026, 12:43 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.82
Real-time Price: $14.89 info
Change: +$2.08 (+16%) info
Market Cap: $12.445B info
RDY
Oct 08, 2026, 9:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.27
Real-time Price: $14.89 info
Change: +$2.62 (+21%) info
Market Cap: $12.445B info